Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer

被引：0
|
作者：
Zhou, J. [1 ]
Zong, Y. [1 ]
Yuan, J. [1 ]
Peng, Z. [1 ]
Lu, M. [1 ]
Wang, X. [1 ]
Shen, L. [1 ]
机构：
[1] Beijing Canc Hosp, Dept Gastrointestinal Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
194P
引用
收藏
页码：S1315 / S1315
页数：1
相关论文
共 50 条
  • [41] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, Werner
    Kornek, Gabriela
    Prager, Gerald
    Stranzl, Nadja
    Laengle, Friedrich
    Schindl, Martin
    Friedl, Josef
    Klech, Julia
    Roethlin, Sabine
    Zielinski, Christoph
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (02) : 234 - 238
  • [42] Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial
    Pressiani, T.
    Balsano, R.
    Giordano, L.
    Milella, M.
    Bergamo, F.
    Bozzarelli, S.
    Noventa, S.
    Ferrari, D.
    Scartozzi, M.
    Parra, H. J. Soto
    Auriemma, A.
    Solda, C.
    Zaniboni, A.
    Zecchetto, C.
    Rizzato, M. D.
    Rimassa, L.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S120 - S120
  • [43] Pd-1 inhibitors plus nab-paclitaxel with S1 (AS) as first line in patients with advanced biliary tract cancer.
    Gou, Miaomiao
    Tie, Liu E.
    Yan, Huan
    Si, Haiyan
    Wang, Zhikuan
    Qian, Niansong
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] A Retrospective Analysis of nab-Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients With Poor Prognostic Factors
    O'Shaughnessy, J.
    Gradishar, W.
    Bhar, P.
    Iglesias, J.
    CANCER RESEARCH, 2012, 72
  • [45] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Yasin
    Karhan, Ogur
    Aldemir, Mehmet Naci
    Urun, Muslih
    Ercek, Berrak Mermit
    Urakci, Zuhat
    Arvas, Hayati
    Tunc, Sezai
    Erdem, Mehmet
    Yerlikaya, Halis
    Ileri, Serdar
    Aydin, Ibrahim
    Bicer, Abdurrahman
    Komuroglu, Ahmet Ufuk
    Majidova, Nargiz
    Gokcek, Savas
    Demir, Hacer
    Yildiz, Sedat
    Akbas, Sinem
    Ozen, Esra
    Kahya, Burcu Ulas
    Sali, Muersel
    Anik, Hicran
    Aykut, Talat
    Araz, Murat
    Alkan, Ali
    Ozcelik, Melike
    Sakin, Abudllah
    Aykan, Musa Baris
    Mehtiyev, Mirmehdi
    Demir, Bilgin
    Baser, Mehmet Nuri
    Sonmez, Muge
    Gulturk, Ilkay
    Avci, Niluever
    Urvay, Semiha
    Arici, Mustafa Ozgur
    Kalender, Mehmet Emin
    Yildirim, Mustafa
    Solmaz, Ali Alper
    Gurbuz, Mustafa
    Ergun, Yakup
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [46] Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
    Petrioli, Roberto
    Torre, Pamela
    Pesola, Guido
    Paganini, Giovanni
    Paolelli, Loretta
    Miano, Salvatora Tindara
    Martellucci, Ignazio
    Francini, Guido
    Francini, Edoardo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (04) : 647 - 651
  • [47] Nab-paclitaxel as second-line treatment in advanced biliary cancer
    Unseld, M.
    Kornek, G.
    Werner, S.
    Guenther, S.
    Christoph, Z.
    Gerald, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S431 - S432
  • [48] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Y.
    Karhan, O.
    Urakci, Z.
    Mecidova, N.
    Araz, M.
    Sakin, A.
    Ercek, B. M.
    Urun, M.
    Urvay, S.
    Aykan, M. B.
    Kocak, S.
    Arici, M. O.
    Avci, N.
    Alkan, A.
    Ozcelik, M.
    Aldemir, M. N.
    Ergun, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S930 - S930
  • [49] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [50] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma
    Cho, JY
    Paik, YH
    Chang, YS
    Lee, SJ
    Lee, DK
    Song, SY
    Chung, JB
    Park, MS
    Yu, JS
    Yoon, DS
    CANCER, 2005, 104 (12) : 2753 - 2758
12345